Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology, 40(15), 1696–1698. https://doi.org/10.1200/jco.22.00503
Subjects:
Cancer Immunotherapy
(OpenAlex Topic)
Economic Burden of Cancer Treatment
(OpenAlex Topic)
Molecular Research on Breast Cancer
(OpenAlex Topic)
Breast Neoplasms
(MeSH)
Publication Type:
Article
Unique ID:
10.1200/JCO.22.00503
PMID:
DOI:
Journal:
Publication Date:
Data Source:
Web of Science
Source Link: